Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis

Abstract

Clinically isolated syndromes (CIS) are events suggestive for emerging multiple sclerosis (MS). A majority of patients develop MS within months or years whilst others remain clinically isolated. The goal of this study was to investigate whether biochemical metabolites detectable by 1H magnetic resonance spectroscopy (MRS) may serve to distinguish between these two groups. We investigated 41 patients 14 years after presentation with a CIS and 21 controls with combined quantitative short echo 1H MRS and magnetic resonance imaging (MRI) and assessed disability according to the Expanded Disability Status Scale (EDSS). At follow-up, 32 had developed MS, and 9 still had CIS. Compared with controls, MS patients demonstrated significantly higher concentrations of myo-inositol (Ins) in normal appearing white matter (NAWM) and lesions. Lesions also demonstrated a reduced N-acetyl-aspartate (NAA) level and an increase in choline-containing compounds (Cho). The NAWM Ins concentration was correlated with EDSS (r = 0.48, p = 0.005). MS normal appearing cortical grey matter (CGM) exhibited a decreased NAA. Patients who remained CIS did not differ significantly from controls in any MRS measure. Metabolite changes in normal appearing white and grey matter in MS indicate diffuse involvement of the entire MS brain, which was not seen in the persisting CIS patients. Elevated Ins in MS NAWM appeared functionally relevant. It may indicate glial cell proliferation or gliosis.

Keywords

Clinically isolated syndrome magnetic resonance spectroscopy multiple sclerosis

Get full access to this article

View all access options for this article.

References

Ormerod I , Miller D , McDonald W , et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions: a quantitative study . Brain 1987; 110: 1579-1616 .

Miller D , Ormerod I , Rudge P , Kendall B , Moseley I , McDonald W. The early risk of multiple sclerosis following isolated syndromes of the brainstem and spinal cord . Ann Neurol 1989; 26: 635-639 .

Sharief M , Thompson E. The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis . Ann Neurol 1991; 29: 147-151 .

Morrissey S , Miller D , Kendall B , et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis—a 5-year follow-up study . Brain 1993; 116: 135-146 .

Filippi M , Horsfield M , Morrissey S , et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis . Neurology 1994; 44: 635-641 .

O’Riordan J , Thompson A , Kingsley D , et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up . Brain 1998; 121: 495-503 .

Brex P , O’Riordan J , Miszkiel K , et al. Multi-sequence MRI in clinically isolated syndromes and the early development of MS . Neurology 1999; 53: 1184-1190 .

Kinkel R , Simon J , Baron B. Bimonthly cranial MRI activity following an isolated monosymptomatic demyelinating syndrome: potential outcome measures for future multiple sclerosis prevention trails . Mult Scler 1999; 5: 307-312 .

Tintoré M , Rovira A , Martínez M , et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis . AJNR Am J Neuroradiol 2000; 21: 702-706 .

10.

Barkhof F , Filippi M , Miller D , et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis . Brain 1997; 120: 2059-2069 .

11.

Brex P , Miskiel K , O’Riordan J , et al. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI . J Neurol Neurosurg Psychiatry 2001; 70: 390-393 .

12.

Brex P , Gomez-Anson B , Parker G , et al. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis . J Neurol Sci 1999; 166: 16-22 .

13.

Fu L , Matthews P , DeStefano N , et al. Imaging axonal damage of normal appearing white matter in multiple sclerosis . Brain 1998; 121: 103-113 .

14.

Narayana P , Doyle T , Lai D , Wolinsky J. Serial proton magnetic resonance spectroscopic imaging, contrast enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis . Ann Neurol 1998; 43: 56-71 .

15.

Kapeller P , McLean M , Griffin C , et al. Evidence for neuronal damage in cortical grey matter and normal appearing white matter in early relapsing remitting multiple sclerosis: a quantitative MR spectroscopic imaging study . J Neurol 2001; 248: 131-138 .

16.

De Stefano N , Narayanan S , Francis G , et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability . Arch Neurol 2001; 58: 65-70 .

17.

Helms G , Stawiarz L , Kivisäkk P , Link H. Regression analysis of metabolite concentrations estimated from localized proton MR spectra of active and chronic multiple sclerosis lesions . MRM 2000; 43: 102-110 .

18.

Poser C , Paty D , Scheinberg L , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

19.

Rooney W , Goodkin D , Schuff N , Meyerhoff D , Norman D , Weiner M. 1H-MRSI of normal appearing white matter in multiple sclerosis . Mult Scler 1997; 3: 231-237 .

20.

Davie C , Barker G , Thompson A , Tofts P , McDonald W , Miller D. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis . J Neurol Neurosurg Psychiatry 1997; 63: 736-742 .

21.

Thompson A , Montalban X , Barkhof F , et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper . Ann Neurol 2000; 47: 831-835 .

22.

Leary S , Davie C , Parker G , et al. 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis . J Neurol 1999; 246: 1023-1026 .

23.

Suhy J , Rooney W , Goodkin D , et al. 1H MRSI comparison of white matter and lesions in primary progressive and relapsingremitting MS . Mult Scler 2000; 6: 148-155 .

24.

Brand A , Richter-Landsberg C , Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells . Dev Neurosci 1993; 15: 289-298 .

25.

Miller B , Moats R , Shonk T , Ernst T , Wooley S , Ross B. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy . Radiology 1993; 187: 433-437 .

26.

Behar K , Boucher R , Fritch W , Manuelidis L. Changes in N-acetyl-aspartate and myo-inositol detected in the cerebral cortex of hamsters with Creutzfeld-Jakob disease . MRI 1998; 16: 963-968 .

27.

Allen I , McKeown S. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis . J Neurol Sci 1979; 41: 81-91 .

28.

Matthews P , Pioro E , Narayanan S , et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy . Brain 1996; 119: 715-722 .

29.

Bitsch A , Bruhn H , Vougioukas V , et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy . AJNR 1999; 20: 1619-1627 .

30.

Simmons M , Frondoza C , Coyle J. Immunocytochemical local-isation of N-acetyl-aspartate with monoclonal antibodies . Neuroscience 1991; 45: 37-45 .

31.

Kidd D , Barkhof F , McConnell R , Algra P , Allen I , Reversz T. Cortical lesions in multiple sclerosis . Brain 1999; 122: 17-26 .

32.

Bo L , Nyland H , Veleler C , Trapp B , Mork S. Extensive cortical demyelination in multiple sclerosis . Rev Neurol 2000; 156(Suppl 3): S25-S25 .